New shot shows promise for shedding pounds in Mid-Stage trial
NCT ID NCT07281495
First seen Jan 05, 2026 · Last updated May 11, 2026 · Updated 24 times
Summary
This study tests an investigational drug called taldefgrobep alfa to see if it helps adults with overweight or obesity lose weight. About 150 participants will receive either the drug or a placebo by injection for 24 weeks, with an option to continue in an open-label extension. The main goal is to measure the percentage change in total body weight from the start to week 24.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site-001
Chula Vista, California, 91911, United States
-
Site-002
Fargo, North Dakota, 58104, United States
-
Site-003
Springfield, Missouri, 65807, United States
-
Site-004
Arlington, Virginia, 22205, United States
-
Site-005
Austin, Texas, 78745, United States
-
Site-006
City of Saint Peters, Missouri, 63303, United States
-
Site-007
Chicago, Illinois, 60625, United States
-
Site-008
Palm Springs, Florida, 33461, United States
-
Site-009
Metairie, Louisiana, 70006, United States
-
Site-010
Baton Rouge, Louisiana, 70808, United States
-
Site-011
Sacramento, California, 95821, United States
-
Site-012
McKinney, Texas, 75069, United States
-
Site-013
San Antonio, Texas, 78229, United States
-
Site-014
Montclair, California, 97163, United States
-
Site-015
St. Petersburg, Florida, 33704, United States
-
Site-016
Indianapolis, Indiana, 46254, United States
-
Site-017
North Charleston, South Carolina, 29405, United States
-
Site-018
Tustin, California, 92780, United States
-
Site-019
Monroe, North Carolina, 28112, United States
-
Site-020
Orlando, Florida, 32804, United States
Conditions
Explore the condition pages connected to this study.